Open Orphan PLC Investor Event Attendance and Presentation
10 September 2019 - 4:02PM
RNS Non-Regulatory
TIDMORPH
Open Orphan PLC
10 September 2019
10 September 2019
Open Orphan Plc
("Open Orphan" or the "Company")
Investor Event Attendance and Presentation
Open Orphan presents at the ShareSoc Growth Company Seminar and
the London South East Biotech Investor Evening
Open Orphan, a European-focussed, rare and orphan drug
consulting services platform, is pleased to announce that on
Wednesday 11(th) September the Company will be attending and
presenting at the ShareSoc Growth Company Seminar at 65 Gresham
Street, London, EC2V 7NQ from 17:30 and will also be attending and
presenting at the London South East Biotech Investor Evening at
Brewers Hall, Aldermanbury Square, London EC2V 7HR from 18:30.
Cathal Friel, Open Orphan's Chief Executive Officer, will be in
attendance throughout both events and will be presenting to update
existing and potential investors on the Company's business plans
for 2019-2020.
The events will provide an opportunity for investors to hear
about the progress being made by the Company following the reverse
takeover of Venn Life Sciences and the potential for Open Orphan
moving forward.
A link to the presentation will be made available on the Company
website following the events.
For further information on the events, please visit the
respective event website:
-
https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-london-11-september-2019/
- https://www.lse.co.uk/events/
Enquiries:
Open Orphan Plc Tel: +353 (0)1 644 0007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44
(0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1
679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focussed, rare and orphan drug
consulting services platform. The Company consists of four
elements: a European clinical research organisation and
consultancy; an orphan drug services business; a Virtual Rep and
Data Access Platform consisting of physicians and key opinion
leaders; and a Health Data Platform to partner with Patient
Advocacy Groups. The Company is targeting rapid growth in one of
the fastest growing sectors in the global pharmaceutical industry
targeting under-supplied treatment for life threatening or very
serious diseases and rare disorders.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUGUMGBUPBGQB
(END) Dow Jones Newswires
September 10, 2019 02:02 ET (06:02 GMT)
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From Apr 2024 to May 2024
Venn Life Sciences (LSE:VENN)
Historical Stock Chart
From May 2023 to May 2024